Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo

Journal of Experimental Therapeutics and Oncology

Volumn 5, Issue 4, 2006, Pages 261-272

  Papadopoulou, Maria V ^a   Ji, Xinhai ^a   Bloomer, William D ^a  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

Alkylating agents; Hypoxic cytotoxins; NLCQ 1; Synergy; Tirapazamine

Indexed keywords

4 [3 (2 NITRO 1 IMIDAZOLYL)PROPYLAMINO] 7 CHLOROQUINOLINE; ALKYLATING AGENT; CELL DNA; CISPLATIN; IMIDAZOLE DERIVATIVE; MELPHALAN; NLCQ 1; QUINOLINE DERIVATIVE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CELL HYPOXIA; CELL STRAIN V 79; COMET ASSAY; CONTROLLED STUDY; DNA CROSS LINKING; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR MODEL;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CISPLATIN; COMET ASSAY; CRICETINAE; DRUG SYNERGISM; FEMALE; IMIDAZOLES; MELPHALAN; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; QUINOLINES; TRIAZINES;

EID: 33749328265     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Bussink J, Kaanders JHAM, van der Kogel AJ. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers (Review). Radioth Oncol 67: 3-15, 2003.
2. Hockel M, Schlenger K, Mitze M, Schaffer U, Vaupel P. Hypoxia and radiation response in human tumors. Seminars in Radiat Oncol 6: 3-9, 1996.
3. Graham CH, Forsdike J, Fitzgerald CJ, MacDonald-Goodfellow S. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer 80: 617-623, 1999.
4. Grau C, Overgaard J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol 13: 301-309, 1988.
5. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of uterine cervix. Cancer Res 56: 4509-4515, 1996.
6. Stratford IJ, Workman P. Bioreductive drugs into the next millennium. Anticancer Drug Design 13: 519-528, 1998.
7. Holden SA, Teicher BA, Ara G, Herman TS, Coleman CN. Enhancement of alkylating agent activity by SR-4233 in FSaIIC murine fibrosarcoma. J Nat Cancer Inst 84: 187-193, 1992
8. Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR4233) and cisplatin. Cancer Res 53: 4633-4636, 1993.
9. Langmuir VK, Rooker JA, Osen M, Mendonca HL, Laderoute K. Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts. Cancer Res 54: 2845-2847, 1994
10. Siemann DW. Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872. Radiother Oncol 34: 47-53, 1995.
11. Siemann DW. The in situ tumor response to combinations of cyclophosphamide and tirapazamine. Br J Cancer 74(Suppl. XXVII): S65-S69, 1996.
12. Siemann DW, Hinchman CA. Potentiation of cisplatin activity by the bioreductive agent tirapazamine. Radioth Oncol 47: 215-220, 1998.
13. Lartigau E, Guichard M. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumors. Br J Cancer 73: 1480-1485, 1996.
14. Papadopoulou MV, Ji M, Bloomer WD. THNLA-1 as radio/chemosensitizer of EMT6 tumors in mice. Br J Cancer 74(Suppl. XXVII): S267-S270, 1996.
15. Papadopoulou MV, Ji M, Bloomer WD. THNLA-1: A DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo. In Vivo 10: 49-58, 1996.
16. Papadopoulou MV, Ji M, Rao MK, Bloomer WD. 9-[3-(2-Nitro-1-imidazolyl)- propylamino]cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): A novel DNA-affinic bioreductive agent as chemosensitizer. 1. Oncol Res 9: 249-257, 1997.
17. Dorie MJ, Brown JM. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol 39: 361-366, 1997.
18. Papadopoulou MV, Ji M, Bloomer WD. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo. Int J Radiat Oncol Biol Phys 42: 775-779, 1998.
19. Kovacs MS, Hocking DJ, Evans JW, Sum BG, Wouters BG, Brown JM. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br J Cancer 80: 1245-1251, 1999.
20. Papadopoulou MV, Ji M, Bloomer WD. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice. Cancer Chemother Pharmacol 48(2): 160-168, 2001.
21. Friery OP, Gallagher R, Murray MM, Hughes CM, Galligan ES, McIntyre IA, Patterson LH, Hirst DG and McKeown. Enhancement of the anti-tumor effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine. Br J Cancer 82(8): 1469-1473, 2000.
22. Gallagher R, Hughes CM, Murray MM, Friery OP, Patterson LH, Hirst DG and McKeown SR. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br J Cancer 85: 625-629, 2001.
23. Miller VA, Ng KK, Grant SC, Kindler H, Pizzo B, Heelan RT, von Roemeling R, Kris MG. Phase 11 study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 8: 1269-1271, 1997.
24. Treat J, Johnson E, Langer C, Belani C, Haynes B, Greenberg R, Rodriquez R, Drobins P, Miller W, Jr Meehan L, McKeon A, Devin J, von Roemeling R, Viallet J. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase 11 study. J Clin Oncol 16: 3524-3527, 1998.
25. von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman B, Ayoub J, Richardson G, Dunlop D, Arcenas A, Vescio R, Viallet J, Treat J. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT 1 study group. J Clin Oncol 18: 1351-1359, 2000.
26. Rishin D, Peters L, Hicks R, Hughes P, Fisher R, Hart R, Sexton M, D'Costa I, von Roemeling R. Phase 1 trial of concurrent tirapazamine, cisplatin and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 19: 535-542, 2001.
27. Covens A, Blessing J, Bender D, Mannel R, Morgan M. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecologic Oncol 100(3): 586-90, 2006.
28. Papadopoulou MV, Bloomer WD. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug [Review]. Clin Cancer Res 9: 5714-5720, 2003.
29. Papadopoulou MV, Bloomer WD. Exploiting hypoxia in solid tumors with DNA-targeted bioreductive drugs [Review], Drugs of the Future 29(8): 807-819, 2004.
30. Papadopoulou MV, Ji M, Ji X, Bloomer WD and Hollingshead MG. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice. Cancer Chem Pharmacol 50: 501-508, 2002.
31. Papadopoulou MV, Ji M, Ji X, Bloomer WD. Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo. Comparison with tirapazamine. Cancer Chem Pharmacol 50: 291-298, 2002.
32. Papadopoulou MV, Ji M, Rao MK, Bloomer WD. 4-[3-(2-Nitro-1-imidazolyl)- propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol Res 12: 185-192, 2000.
33. McKeage MJ. Comparative adverse effect profiles of platinum drugs (Review). Drug safety 13: 228-244, 1995.
34. Hirst DG, Brown JM, Hazlehurst JL. Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of 1-(2-chloroethyl)-3- cyclohexyl-1-nitrosourea. Cancer Res 43: 1961-1965, 1983.
35. Olive PL. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine. Br J Cancer 71:529-536, 1995.
36. Papadopoulou MV, Ji M, Bloomer WD. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1 in vivo: Comparison with tirapazamine. Oncol Res 13: 47-54, 2002.
37. Olive PL. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. II. RSU 1069. Br J Cancer 71: 537-542, 1995.
38. 2]. Science 218(4577): 1075-1082, 1982.
39. Papadopoulou MV, Ji X, Bloomer WD. Mechanisms involved in the potentiation of paclitaxel or 5FU by the hypoxic cytotoxin NLCQ-1 (NSC 709257) in vitro. Anticancer Res 25: 2161-2170, 2005.
40. Aboagye EO, Maxwell RJ, Kelson AB, Tracy M, Lewis AD, Graham MA, Horsman MR, Griffiths JR, Workman P. Preclinical evaluation of fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for measurement of tumor hypoxia. Cancer Res 57: 3314-3318, 1997.
41. Denny WA. Prodrug strategies in cancer therapy [Review]. Eur J Med Chem 36: 577-595, 2001.
42. Papadopoulou MV, Ji M, Rao MK, Bloomer WD. Reductive activation of the nitroimidazole-based hypoxia-selective cytotoxin NLCQ-1 (NSC 709257). Oncol Res 14: 21-29, 2003.
43. Papadopoulou MV, Ji M, Khan SH, Bloomer WD. Mechanistic studies regarding the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro. Oncol Res 11: 345-357, 1999.
44. Papadopoulou MV, Rosenzweig HS, Ji M, Shariq KH, Bloomer WD. 9-[3-(2-Nitro-1-imidazolyl) propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as chemosensitizer: Mechanistic studies. II. Oncol Res 10: 163-173, 1998.